A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01922843

Acronym

2MD-7H-2B

Enrollment

Registered

2013-08-14

Start date

2013-09-30

Completion date

2014-06-30

Last updated

2017-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperparathyroidism, Secondary, Kidney Failure, Chronic

Keywords

Hemodialysis

Brief summary

The goal of this study is to test a new vitamin D compound for its ability to reduce parathyroid hormone levels in patients who are on hemodialysis.

Detailed description

This is a randomized, double-blind, placebo-controlled study of the vitamin D analog 2-methylene-19-nor-20S-1α,25-dihydroxyvitamin D3 (DP001) in patients with end-stage renal disease (ESRD). The effect of 12 weeks of oral administration of DP001 on serum parathyroid hormone (PTH) levels will be evaluated in ESRD patients who have secondary hyperparathyroidism.

Interventions

DRUGDP001 softgel capsules

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Men and non-pregnant women ≥18 years of age * Patient is diagnosed with ESRD and must be on hemodialysis 3 times per week for at least 3 months prior to Screening Phase * Patient is currently being treated with pharmaceutical vitamin D for the treatment of secondary hyperparathyroidism * Serum iPTH value ≤500 pg/mL at first screening visit * Total serum calcium (corrected for albumin) ≤10.5 mg/dL at first screening visit * Serum phosphorus ≤7.0 mg/dL at first screening visit

Exclusion criteria

* Currently taking any of the following: drugs affecting vitamin D metabolism, digitalis, glucocorticoids, cyclosporine or other immunosuppressants, aluminum-based phosphate binders * A daily intake \>4000 IU vitamin D (D3 + D2) * Any investigational drug use within 10 half-lives of the drug (or within the previous 30 days if the half-life of the drug is unknown) * History of any of the following: ventricular dysrhythmias, severe congestive heart failure, angina pectoris, myocardial infarction, coronary angioplasty, coronary artery bypass grafting, multiple myeloma, calciphylaxis, active malignancy, end-stage liver disease, active infections, clinically significant renal/urinary tract stones, sarcoidosis, tuberculosis, parathyroidectomy * Major surgery within the past 3 months

Design outcomes

Primary

Measure	Time frame
The proportion of patients who achieve two consecutive > or = 30% decreases from his/her baseline serum iPTH level	12 weeks, with weekly iPTH measurements

Secondary

Measure	Time frame
Mean percentage change in serum iPTH	Baseline to 12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026